Ep. 259 Prostate Tumor Board: Risk Stratification & Treatment Strategies with Dr. Neeraj Agarwal and Dr. Tyler Seibert

Could ongoing trials redefine the management of oligometastatic and advanced prostate cancer? In this installment of BackTable Tumor Board, leading prostate cancer experts Dr. Neeraj Agarwal, a medical oncologist from the University of Utah, and Dr. Tyler Seibert, a radiation oncologist from UC San Diego, join host Dr. Parth Modi to share their insights on the latest clinical trials and persistent challenges in managing prostate cancer.

---

This podcast is supported by:
Ferring Pharmaceuticals

---

SYNPOSIS

The multidisciplinary discussion addresses clinical decision-making in active surveillance versus early intervention, the role of PSMA PET imaging in detection and treatment planning, and evolving strategies for metastatic and castration-resistant disease. They also evaluate the therapeutic potential of alpha emitters and radioligand therapies, consider the evidence behind treatment intensification and de-intensification, and explore how these approaches can be individualized to optimize patient outcomes.

---

TIMESTAMPS

0:00 - Introduction
1:48 - Active Surveillance in Low-Risk Prostate Cancer
7:08 - Molecular Testing and Risk Stratification
8:28 - Radiation Therapy Approaches
20:16 - PSA Recurrence and PSMA PET Scans
32:40 - The Role of ADT
37:15 - PSMA PET Scans
40:58 - Genetic Testing in High-Risk and Metastatic Prostate Cancer
46:54 - Treatment Intensification vs. De-Intensification Trials
55:59 - Castration-Resistant Prostate Cancer